$4.40
0.051.15%
Pre-Market: 7:33 AM EDT
Comments
Loading...
Karyopharm Therapeutics Stock Guidance | NASDAQ:KPTI | Benzinga
Karyopharm Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/19/2025 | KPTI | Karyopharm Therapeutics | FY | 2025 | — | — | — | $140.00M | $155.00M | $165.50M | Get Alert |
| 01/13/2025 | KPTI | Karyopharm Therapeutics | FY | 2024 | — | — | — | $145.00M | $145.00M | $152.89M | Get Alert |
| 01/13/2025 | KPTI | Karyopharm Therapeutics | Q4 | 2024 | — | — | — | $30.00M | $30.00M | $38.20M | Get Alert |
| 11/05/2024 | KPTI | Karyopharm Therapeutics | FY | 2024 | — | — | — | $145.00M | $155.00M | $152.35M | Get Alert |
| 08/06/2024 | KPTI | Karyopharm Therapeutics | FY | 2024 | — | — | — | $145.00M | $160.00M | $145.44M | Get Alert |
| 05/08/2024 | KPTI | Karyopharm Therapeutics | FY | 2024 | — | — | — | $140.00M | $160.00M | $146.52M | Get Alert |
| 02/29/2024 | KPTI | Karyopharm Therapeutics | FY | 2024 | — | — | — | $140.00M | $160.00M | $152.02M | Get Alert |
| 01/08/2024 | KPTI | Karyopharm Therapeutics | Q4 | 2023 | — | — | — | $33.60M | $33.60M | $37.64M | Get Alert |
| 01/08/2024 | KPTI | Karyopharm Therapeutics | FY | 2023 | — | — | — | $146.00M | $146.00M | $150.03M | Get Alert |
| 11/02/2023 | KPTI | Karyopharm Therapeutics | FY | 2023 | — | — | — | $145.00M | $160.00M | $151.17M | Get Alert |
| 08/02/2023 | KPTI | Karyopharm Therapeutics | FY | 2023 | — | — | — | $145.00M | $160.00M | $150.34M | Get Alert |
| 05/04/2023 | KPTI | Karyopharm Therapeutics | FY | 2023 | — | — | — | $145.00M | $160.00M | $157.37M | Get Alert |
| 02/15/2023 | KPTI | Karyopharm Therapeutics | FY | 2023 | — | — | — | $160.00M | $175.00M | $163.24M | Get Alert |
| 01/09/2023 | KPTI | Karyopharm Therapeutics | Q4 | 2022 | — | — | — | $34.20M | $34.20M | $38.13M | Get Alert |
| 01/09/2023 | KPTI | Karyopharm Therapeutics | FY | 2022 | — | — | — | $157.70M | $157.70M | $161.68M | Get Alert |
| 11/03/2022 | KPTI | Karyopharm Therapeutics | FY | 2022 | — | — | — | $155.00M | $165.00M | $157.23M | Get Alert |
| 08/04/2022 | KPTI | Karyopharm Therapeutics | FY | 2022 | — | — | — | $155.00M | $165.00M | $160.03M | Get Alert |
| 01/11/2021 | KPTI | Karyopharm Therapeutics | FY | 2020 | — | — | — | $108.00M | $109.00M | $98.14M | Get Alert |
| 01/11/2021 | KPTI | Karyopharm Therapeutics | Q4 | 2020 | — | — | — | $35.00M | $36.00M | $24.91M | Get Alert |
FAQ
What is the most recent guidance for Karyopharm Therapeutics (KPTI)?
There have been no specific sales or earnings guidance reported for Karyopharm Therapeutics in recent months.
Browse guidance and forecast on all stocks.